The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma
# Background Rising oncology healthcare costs have led to value-based care reimbursement models that coordinate care and improve quality while reducing overall spending. These models are increasingly important for traditional Medicare and other payers. # Objectives To compare the incidence of adver...
Saved in:
| Main Authors: | Prachi Bhatt, Jared Hirsch, Paul Cockrum, George Kim, Gabriela Dieguez |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2024-12-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.124367 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
by: Syvart Dennen, et al.
Published: (2025-08-01) -
Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01) -
Pancreatic ductal adenocarcinoma in colonic wall: metastatic disease or cancerized pancreatic ectopic tissue?
by: Graziana Gallo, et al.
Published: (2020-04-01) -
Understanding the heterogeneity of pancreatic ductal adenocarcinoma
by: Juan Iovanna, et al.
Published: (2025-10-01) -
Features of immunophenotype of pancreatic ductal adenocarcinoma
by: A. V. Evseyev
Published: (2014-12-01)